Literature DB >> 20698884

The perspectives of the application of phage therapy in chronic bacterial prostatitis.

Sławomir Letkiewicz1, Ryszard Międzybrodzki, Marlena Kłak, Ewa Jończyk, Beata Weber-Dąbrowska, Andrzej Górski.   

Abstract

Chronic bacterial prostatitis (CBP) is a long-lasting and crippling disease that strongly impacts the patient's quality of life. The diagnosis of CBP is difficult and the treatment regimens are not always successful. Poor penetration of antibiotics to the prostate tissue, the drug resistance of uropathogens, the adverse events associated with antibiotic treatment, the persistence of prostatic calculi, and biofilm formation in the prostate gland are factors that contribute toward decreasing the cure rate of CBP. The phenomenon of increasing antibiotic resistance, which has also been called a clinical super-challenge, has revived interest in therapy using bacterial viruses (bacteriophages or phages). Because of their mechanism of action, which is completely different from those of all antibiotics, phages are effective even against multidrug-resistant bacteria. Here, we describe the current perspectives on the possible application of phage therapy (PT) in treating CBP. The advantages of therapeutic phages, including their interactions with bacterial biofilm, as well as the safety of PT are discussed.
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698884     DOI: 10.1111/j.1574-695X.2010.00723.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  18 in total

1.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

Review 2.  Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.

Authors:  Katherine M Caflisch; Robin Patel
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

3.  A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.

Authors:  B Mijbel Ali; S A Gatea Kaabi; M A Al-Bayati; H K Musafer
Journal:  Arch Razi Inst       Date:  2021-11-30

4.  Improved adsorption of an Enterococcus faecalis bacteriophage ΦEF24C with a spontaneous point mutation.

Authors:  Jumpei Uchiyama; Iyo Takemura; Miho Satoh; Shin-ichiro Kato; Takako Ujihara; Kazue Akechi; Shigenobu Matsuzaki; Masanori Daibata
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

5.  Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections.

Authors:  Chloe E James; Emily V Davies; Joanne L Fothergill; Martin J Walshaw; Colin M Beale; Michael A Brockhurst; Craig Winstanley
Journal:  ISME J       Date:  2014-12-02       Impact factor: 10.302

6.  Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments.

Authors:  Apurva Virmani Johri; Pranav Johri; Naomi Hoyle; Levan Pipia; Lia Nadareishvili; Dea Nizharadze
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

7.  Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.

Authors:  Sławomir Letkiewicz; Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Maciej Żaczek; Beata Weber-Dąbrowska; Andrzej Górski
Journal:  Antibiotics (Basel)       Date:  2021-05-25

8.  Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus.

Authors:  Amy E Kirby
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 9.  Phage therapy: eco-physiological pharmacology.

Authors:  Stephen T Abedon
Journal:  Scientifica (Cairo)       Date:  2014-05-20

10.  Bacteriophages as Potential Treatment for Urinary Tract Infections.

Authors:  Wilbert Sybesma; Reinhard Zbinden; Nino Chanishvili; Mzia Kutateladze; Archil Chkhotua; Aleksandre Ujmajuridze; Ulrich Mehnert; Thomas M Kessler
Journal:  Front Microbiol       Date:  2016-04-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.